Sansum Diabetes Research Institute
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Sansum Diabetes Research Institute sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Sansum Diabetes Research Institute: 33 sponsored US clinical trials, none currently recruiting.
Sansum Diabetes Research Institute sponsors 33 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 29 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 3 trials.
Top-decile sponsor footprint
Sansum Diabetes Research Institute ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
33 total, page 1 of 1
Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA
NCT05000840
Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes
NCT06218147
Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes
NCT05975242
Continuous Glucose Monitoring and Hass Avocado Trial ("CHAT")
NCT05293340
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
NCT04938388
Assessing Adherence to Digital Health Technologies Among Hispanic/Latino Adults With or At Risk of Type 2 Diabetes:
NCT04820348
The International Diabetes Closed Loop (iDCL) Trial: Protocol 4
NCT04436796
Automated Insulin Delivery in Pregnant Patients With Type 1 Diabetes With Extension Into Outpatient at Home
NCT04492566
Artificial Pancreas With Different Stress Assessments in the Outpatient Setting
NCT04142229
Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy
NCT04016584
Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos
NCT03830840
Farming for Life - Health Impact of Organic Vegetable Prescriptions for Adults Living With or at Risk of Type 2 Diabetes
NCT03940300
Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) With Different Food Choices in the Outpatient Setting
NCT03767790
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
NCT03668808
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy
NCT03761615
Safety and Feasibility Evaluation of the APS APP
NCT03504046
A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)
NCT03362151
Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes
NCT03307850
Mil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community
NCT03736486
Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index
NCT03092310
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
NCT02705053
Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting
NCT02463682
MPC Versus PID for Closed Loop Insulin Delivery
NCT02438670
Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias
NCT02290600
Feasibility Study of PID Versus MPC and HMS
NCT01987206
Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control
NCT02190669
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin
NCT01929798
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
NCT01662921
Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2
NCT01831752
Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp
NCT01874392
Outpatient Control-to-Range: System and Monitoring Testing
NCT01697150
Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)
NCT01472406
Controlled Insulin Delivery: Combining Technology With Treatment
NCT01484457
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
How the Sansum Diabetes Research Institute early-phase archive is shaped
33 indexed studies, none listed as recruiting (0% open); 29 completed (88%).
Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Type 1 Diabetes Mellitus (3 trials), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Sansum Diabetes Research Institute: archived-pipeline peers nationwide
Peers matched on 33 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Sansum Diabetes Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 archived trials
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Sansum Diabetes Research Institute page
33 registered trials is a research-attention snapshot, not an endorsement of Sansum Diabetes Research Institute or any single study.
- None of Sansum Diabetes Research Institute's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Type 1 Diabetes Mellitus is the condition Sansum Diabetes Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sansum Diabetes Research Institute pipeline card: 33 registered trials from official public datasets.Report a data error.